Application of fragment screening by X-ray crystallography to β-secretase

被引:122
作者
Murray, Christopher W. [1 ]
Callaghan, Owen [1 ]
Chessari, Gianni [1 ]
Cleasby, Anne [1 ]
Congreve, Miles [1 ]
Frederickson, Martyn [1 ]
Hartshorn, Michael J. [1 ]
McMenamin, Rachel [1 ]
Patel, Sahil [1 ]
Wallis, Nicola [1 ]
机构
[1] Astex Therapeut Ltd, Cambridge CB4 0QA, England
关键词
STRUCTURE-BASED DESIGN; AMYLOID PRECURSOR PROTEIN; POTENT INHIBITORS; PEPTIDOMIMETIC INHIBITORS; SUBSTITUTED PIPERIDINES; GENETIC ALGORITHM; RENIN INHIBITORS; LEAD DISCOVERY; DRUG DESIGN; BACE;
D O I
10.1021/jm0611962
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
This paper describes an application of fragment screening to the aspartyl protease enzyme, beta-secretase (BACE-1), using high throughput X-ray crystallography. Three distinct chemotypes were identified by X-ray crystallography as binding to the catalytic aspartates either via an aminoheterocycle (such as 2-aminoquinoline), a piperidine, or an aliphatic hydroxyl group. The fragment hits were weak inhibitors of BACE-1 in the millimolar range but were of interest because most of them displayed relatively good ligand efficiencies. The aminoheterocycles exhibited a novel recognition motif that has not been seen before with aspartic proteases. Virtual screening around this motif identified an aminopyridine with increased potency and attractive growth points for further elaboration using structure-based drug design. The companion paper illustrates how sub-micromolar inhibitors were developed starting from this fragment.
引用
收藏
页码:1116 / 1123
页数:8
相关论文
共 66 条
[1]  
ALBERT JS, 2006, Patent No. 2006065204
[2]   THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].
BAILEY, S .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763
[3]   Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening [J].
Boehm, HJ ;
Boehringer, M ;
Bur, D ;
Gmuender, H ;
Huber, W ;
Klaus, W ;
Kostrewa, D ;
Kuehne, H ;
Luebbers, T ;
Meunier-Keller, N .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (14) :2664-2674
[4]   Using fragment cocktail crystallography to assist inhibitor design of Trypanosoma brucei nucleoside 2-deoxyribosyltransferase [J].
Bosch, Jurgen ;
Robien, Mark A. ;
Mehlin, Christopher ;
Boni, Erica ;
Riechers, Aaron ;
Buckner, Frederick S. ;
Van Voorhis, Wesley C. ;
Myler, Peter J. ;
Worthey, Elizabeth A. ;
DeTitta, George ;
Luft, Joseph R. ;
Lauricella, Angela ;
Gulde, Stacey ;
Anderson, Lori A. ;
Kalyuzhniy, Oleksandr ;
Neely, Helen M. ;
Ross, Jenni ;
Earnest, Thomas N. ;
Soltis, Michael ;
Schoenfeld, Lori ;
Zucker, Frank ;
Merritt, Ethan A. ;
Fan, Erkang ;
Verlinde, Christophe L. M. J. ;
Hol, Wim G. J. .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (20) :5939-5946
[5]   Rational design and synthesis of selective BACE-1 inhibitors [J].
Brady, SF ;
Singh, S ;
Crouthamel, MC ;
Holloway, MK ;
Coburn, CA ;
Garsky, VM ;
Bogusky, M ;
Pennington, MW ;
Vacca, JP ;
Hazuda, D ;
Lai, MT .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (03) :601-604
[6]   Designing non-peptide peptidomimetics in the 21st century: Inhibitors targeting conformational ensembles [J].
Bursavich, MG ;
Rich, DH .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (03) :541-558
[7]   Structure-based screening of low-affinity compounds [J].
Carr, R ;
Jhoti, H .
DRUG DISCOVERY TODAY, 2002, 7 (09) :522-527
[8]   Fragment-based lead discovery: leads by design [J].
Carr, RAE ;
Congreve, M ;
Murray, CW ;
Rees, DC .
DRUG DISCOVERY TODAY, 2005, 10 (14) :987-992
[9]   P3 cap modified Phe*-Ala series BACE inhibitors [J].
Chen, SH ;
Lamar, J ;
Guo, DQ ;
Kohn, T ;
Yang, HC ;
McGee, J ;
Timm, D ;
Erickson, J ;
Yip, Y ;
May, P ;
McCarthy, J .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (01) :245-250
[10]   Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration [J].
Clark, DE .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1999, 88 (08) :815-821